Review Papers Claim by Claim

 Quick Answer Copied

 Long Answer

Core Thesis and Supporting Evidence

Bluemn and Nelson's opinion review (Current Opinion in Oncology, 2012) argues that CRPC persists chiefly through re-activation of the AR axis, not through escape from it. They synthesize four resistance mechanisms: (1) AR amplification/overexpression in up to ~60% of CRPC metastases plus a newly identified AR second-intron enhancer creating a low-androgen positive-feedback loop [as reported in the paper]; (2) ligand-binding-domain–deficient splice variants such as AR v567es that translocate constitutively to the nucleus and resist LBD-targeted antagonists; (3) intratumoral androgen synthesis driven by arachidonic-acid/StAR and insulin–StAR pathways; and (4) PTEN-loss/PI3K–AR reciprocal feedback Bluemn & Nelson 2012 review.

The clinical anchor is the phase III abiraterone trial, which reported a median overall survival of 14.8 vs 10.9 months (placebo) after docetaxel, alongside the phase I/II MDV3100 (enzalutamide) data showing 56% PSA response Clinical AR-directed trial data cited in review.

How the Field Has Since Judged the Thesis

The "persistent AR addiction" framing was independently reaffirmed in a later comprehensive review reporting AR copy-number gain in ~45% of metastatic biopsies, AR-V7 in CTCs predicting abiraterone/enzalutamide resistance, and SLCO transporter-mediated androgen uptake — precisely the mechanisms this 2012 piece flagged 2015 persistent AR addiction review. Earlier work had already established that elevated AR converts antagonists to agonists and that AR mRNA is up to ~70-fold higher in metastatic versus primary disease Nature Medicine antiandrogen resistance study.

Critical Assessment, Blind Spots, and Confidence

• Strengths: prescient call for N-terminal AR inhibitors (EPI-001 lineage later led to EPI-506), early emphasis on SLCO2B1/SLCO1B3 transporter pharmacogenetics, and honest acknowledgement that aggressive ADT may select for truly AR-independent tumors.
• Limitations: no original data; narrative selection may overweight supportive studies; mechanistic claims rest on cell lines (LNCaP, VCaP) and xenografts with limited in vivo human validation; the conflicting PI3K–AR feedback models (Carver vs Mulholland) are presented without resolution.
• Blind spots: glucocorticoid receptor bypass, neuroendocrine transdifferentiation, and immune-contexture effects are absent; AR-V7 biomarker conflicts across later studies were not foreseeable Biomarker conflict note.
• Confidence: moderate — the mechanistic synthesis is well-corroborated, but as an opinion piece it cannot itself establish causation; falsification would require demonstrating CRPC growth persisting without any AR output in diverse models.

Deep Paper ReviewGraph AR AlterationsMeta-analyze CRPC Trials

Author Review: Eric G. BluemnAuthor Review: Peter S. Nelson

 BGPT Paper Review

Study Novelty

The AR-centric resistance framing was established by 2001–2009 reviews, but the 2012 piece adds genuinely fresh elements (AR intronic enhancer feedback, AR v567es, insulin/StAR steroidogenesis, SLCO transporters) synthesized at a pivotal clinical moment.

Scientific Quality

Carefully referenced opinion piece from leaders in the field; no original data, unresolved contradictions between Carver and Mulholland models are transparently flagged, and some claims depend on in vitro/xenograft models; conflicts of interest declared as none with listed funding.

Study Generality

Mechanisms (receptor amplification, splice variants, intratumoral ligand synthesis, pathway cross-talk) generalize to nuclear-receptor-driven cancers broadly, not just prostate.

Study Usefulness

Directed research toward N-terminal AR inhibitors, combination ADT, and transporter/steroidogenesis targets; clinically anchored in phase III abiraterone data.

Study Reproducibility

A narrative review presents no methods or data; reproducibility applies only to its cited primary studies.

Explanatory Depth

Mechanistic detail is high for the enhancer-feedback and splice-variant sections, but PI3K–AR cross-talk is left with competing models and HER-kinase effects are acknowledged as incompletely understood.